Clinical Trial Update: A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread [Phase 2]

View source ↗

Summary

A completed Phase 2 trial evaluated nilotinib for metastatic acral lentiginous melanoma and mucosal melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acral Lentiginous Melanoma
• Mucosal Melanoma

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: Institute of Cancer Research, United Kingdom | Conditions: Mucosal Lentiginous Melanoma, Acral Lentiginous Malignant Melanoma | Phase 2 | Status: COMPLETED